drugset / Trial / NCT00934076
Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study the safety and effectiveness of oral AT-101 when given with the standard dose of erlotinib (Tarceva)to patients who are older that 18 and who have advanced non-small cell lung cancer, who have relapsed or progressed on prior platinum-based chemotherapy. It is proposed that the effects of AT-101 may improve the clinical benefit of erlotinib in patients with advanced NSCLC.
Timeline
- Start
- 2010-02
- Primary completion
- 2011-01
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AT-101 | Small molecule | 40 mg | Oral |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |